Top Page
Dimerix Limited
(Sydney:DXB)
Dimerix Limited (DXB) vs. iShares MSCI Australia ETF (EWA)
Dimerix Limited Business Overview & Revenue Model
Dimerix Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.42M | 1.25M | 583.48K | 36.79K | 6.46M | 4.44M |
| Gross Profit | 5.30M | 1.25M | 583.48K | 36.79K | 6.41M | 4.39M |
| EBITDA | -40.31M | -36.22M | -24.96M | -22.68M | -16.47M | -10.02M |
| Net Income | -16.31M | -13.25M | -17.07M | -13.80M | -10.49M | -6.37M |
Balance Sheet | ||||||
| Total Assets | 64.56M | 91.18M | 32.08M | 17.76M | 16.50M | 9.42M |
| Cash, Cash Equivalents and Short-Term Investments | 38.49M | 68.28M | 22.14M | 7.99M | 9.63M | 5.25M |
| Total Debt | 33.42K | 97.48K | 149.68K | 5.96M | 73.10K | 5.09M |
| Total Liabilities | 66.24M | 77.80M | 13.89M | 11.79M | 2.07M | 7.95M |
| Stockholders Equity | -1.68M | 13.38M | 18.19M | 5.96M | 14.42M | 1.47M |
Cash Flow | ||||||
| Free Cash Flow | 11.43M | 39.03M | -7.02M | -12.73M | -13.45M | -6.47M |
| Operating Cash Flow | 11.44M | 39.05M | -7.00M | -12.73M | -13.44M | -6.46M |
| Investing Cash Flow | -10.56K | -21.01K | -15.80K | -2.30K | -10.61K | 4.38K |
| Financing Cash Flow | 6.38M | 7.42M | 21.17M | 11.07M | 17.69M | 3.83M |
Dimerix Limited Technical Analysis
Dimerix Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$502.51M | 15.41 | 15.90% | 0.38% | 7.76% | 1.55% | |
52 Neutral | AU$98.99M | -11.71 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$567.38M | -6.72 | -35.86% | ― | ― | -19.21% | |
48 Neutral | AU$285.19M | -17.46 | -83.97% | ― | 1271.12% | 36.87% | |
44 Neutral | AU$448.80M | -46.00 | -27.89% | ― | ― | 67.26% | |
41 Neutral | AU$257.74M | -18.66 | -89.70% | ― | 42.05% | -0.84% |
Dimerix Limited Corporate Events
Dimerix Limited will present an update on its Phase 3 ACTION3 trial of DMX-200 for FSGS kidney disease at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference in New York and virtually on 27 February 2026. CEO Dr Nina Webster will outline trial recruitment progress by country, planned blinded statistical powering review, commercial partnering status, and broader company growth strategy, underscoring the company’s push to advance a potential first disease-modifying therapy in a rare kidney indication with no approved targeted treatments.
The Phase 3 ACTION3 study is designed as a global, randomised, double-blind, placebo-controlled trial evaluating DMX-200’s impact on proteinuria reduction and kidney function over two years in patients already receiving angiotensin II receptor blockers. Successful results could position Dimerix as a key player in the FSGS treatment landscape, where high unmet need, orphan designations and long patent life create a potentially attractive commercial opportunity for partners and investors.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.44 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Biotechnology developer Dimerix Limited reported a sharp increase in revenue from ordinary activities for the half-year to 31 December 2025, with income rising 388% to $2.32 million. However, the company remains deeply loss-making, underscoring the high-cost nature of drug development and the lag between early revenue generation and sustainable profitability.
The half-year net loss attributable to shareholders widened 24% to $16.0 million, compared with $12.9 million a year earlier, and net tangible assets per share deteriorated to negative $0.0326 from positive $0.0120. No dividends were paid or declared, highlighting the continued reinvestment of resources into operations and signalling that investors must remain focused on longer-term value creation rather than near-term income.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.44 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced that CEO and Managing Director Dr Nina Webster will present at the Euroz Hartleys Healthcare Forum in Perth, providing an update on the company’s global Phase 3 ACTION3 trial of DMX-200 in FSGS kidney disease, including patient recruitment progress by country, the status of commercial partnering discussions, and the broader company growth strategy. The appearance at a specialist healthcare investor forum underscores Dimerix’s efforts to showcase late-stage clinical progress in a rare kidney disease with high unmet need, potentially strengthening its profile with investors and partners as it seeks to advance DMX-200 toward marketing approval and execute on its commercial and expansion plans.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix reported strong operational progress in the December 2025 quarter as its pivotal ACTION3 Phase 3 trial of DMX-200 in adult FSGS patients reached its full target recruitment of 286 adults, with pediatric enrolment continuing as an independent cohort to potentially broaden the treatment’s label. The company also received positive regulatory feedback from the US FDA confirming that proteinuria reduction remains an acceptable primary endpoint for traditional approval, supported by new PARASOL registry data that reinforce the clinical relevance of proteinuria and may underpin both full and accelerated approval strategies in multiple territories. Financially, Dimerix closed the quarter with AU$38.5 million in cash and net operating outflows of AU$11.1 million, largely driven by clinical milestones and R&D spending, leaving it well funded to continue the ACTION3 trial, maintain an open-label extension that retains most completing patients on DMX-200, and pursue additional pipeline and licensing opportunities amid sector interest highlighted by BioMarin’s planned acquisition of its US partner Amicus Therapeutics.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix has appointed seasoned finance executive Mike Tonroe as Chief Financial Officer and Company Secretary, effective 29 January 2026, in a newly created in-house role aimed at supporting the company’s anticipated growth. Tonroe brings more than three decades of international finance and governance experience across ASX and NASDAQ-listed life sciences companies, including prior CFO and Company Secretary roles at Imugene, Opthea, Genetic Technologies and the Australian Synchrotron, with a strong track record in capital raisings, M&A and strengthening financial controls and governance. The move marks a transition from outsourced finance services to an internal leadership structure, underscoring Dimerix’s maturation as it advances its Phase 3 kidney disease asset DMX-200 and positions itself for expanded capital markets activity and strategic execution.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced that CEO and Managing Director Dr Nina Webster will meet investors and potential partners at the 2026 J.P. Morgan Healthcare Conference in San Francisco, where she plans to provide updates on the company’s global Phase 3 trial of DMX-200 in FSGS kidney disease, its commercial partnering progress, and broader growth strategy. The engagement at a major industry forum underscores Dimerix’s efforts to advance its pivotal ACTION3 Phase 3 study, position DMX-200 for potential marketing approval in a rare kidney disorder with no currently approved targeted therapies in the U.S., and strengthen strategic relationships that could influence future commercialisation and company expansion.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.53 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix has received written feedback from the U.S. Food and Drug Administration confirming that percent reduction in proteinuria at two years is an appropriate primary endpoint to support traditional approval of its Phase 3 candidate DMX-200 in FSGS, with change in eGFR to serve as a secondary endpoint. The agency has requested additional information and documentation to safeguard trial integrity before proceeding with a planned blinded statistical powering analysis for the ACTION3 Phase 3 study, pushing that analysis to early 2026 but reinforcing the regulatory path for DMX-200 in a rare kidney disease with no approved targeted therapies, a development that could be significant for patients and for Dimerix’s positioning in the FSGS treatment landscape.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix has confirmed that BioMarin Pharmaceutical will acquire its US commercial licensing partner, Amicus Therapeutics, in an all-cash deal valuing Amicus at about US$4.8 billion, with the transaction to include the transfer of Amicus’s Dimerix commercial licensing contract and all associated rights and obligations. The US licensing agreement for DMX-200 remains intact, leaving Dimerix eligible for up to US$590 million in milestone and upfront payments plus tiered royalties, while its existing ex-US licensing deals with Advanz Pharma, Taiba and Fuso are unaffected and collectively offer up to around A$1.4 billion in potential payments, bolstering the company’s funding base and strategic position as it advances the Phase 3 ACTION3 trial in FSGS and pursues additional partnering opportunities in unlicensed territories.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has successfully completed the recruitment for its ACTION3 Phase 3 clinical trial, which evaluates the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS). The trial, which involves 286 adult patients, has shown promising interim results, with DMX-200 outperforming placebo in reducing proteinuria, a marker of kidney disease progression. The company plans to seek feedback from the FDA on trial endpoints and potential accelerated approval, positioning itself for regulatory submission and potential commercialization.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced a change in the director’s interest, specifically regarding the acquisition of unlisted options by Director Nina Webster. This change is part of the company’s Omnibus Equity Plan, reflecting strategic moves to align management interests with shareholder value. The issuance of these options, valued at $1,093,500, indicates confidence in the company’s future growth and operational strategies.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the issuance of 3,700,000 unquoted securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is likely aimed at incentivizing employees and aligning their interests with the company’s growth, potentially impacting the company’s operational dynamics and stakeholder engagement.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.